This Science News Wire page contains a press release issued by an organization and is provided to you "as is" with little or no review from Science X staff.

Hormone replacement therapy in patients with Parkinson’s disease

June 8th, 2021
Hormone replacement therapy in patients with Parkinson’s disease
Double immunofluorescence labeling of Syt IV and PRL. Nuclei were counterstained with DAPI. (A) Adenohypophysis of rats from treatment group E2. (B) Adenohypophysis of rats from treatment group E2+L-dopa. (C) Adenohypophysis of intact control animals. Scale bars: 10 μm. E2 - 17b-estradiol; PRL – prolactin; SYT IV – synaptotagmin IV; L-dopa – levodopa. Credit: Bosnian Journal of Basic Medical Sciences

Parkinson's disease is a neurodegenerative disorder characterized by motor and non-motor symptoms. Furthermore, the Parkinson's disease is a second most common neurodegenerative disorder, after Alzheimer's disease.

In the study published in BJBMS, the authors from the Brain Research Laboratory, Institute of Pathophysiology, Medical Faculty, University of Ljubljana, Slovenia used the rat model for Parkinson's disease. The rats were ovariectomized and treated with either estrogen or estrogen and L-dopa to mimic female patients in their postmenopausal stage of life that are on hormone replacement therapy.

L-dopa is a dopamine precursor which is used as the first-line treatment for Parkinson's disease. Estrogen and L-dopa act as opposing regulators of the secretion of prolactin from the pituitary gland. Prolactin is a hormone that plays an important role in the modulation of stress response and emotion regulation, therefore postmenopausal female patients with Parkinson's disease on hormone replacement therapy and receiving L-dopa treatment should be closely monitored for their prolactin levels.

The authors found that high doses of estrogen increase the expression of prolactin in the pituitary gland leading to the formation of pituitary tumors and hyperprolactinemia. Treatment with L-dopa decreased the size of prolactinomas, but it did not affect prolactin expression or its serum concentrations.

The authors also investigated the effect of estrogen and L-dopa on the expression of synaptotagmin IV, an immediate early gene involved in exocytosis whose product is abundant in the pituitary gland and was found to be highly co-expressed with prolactin. Furthermore, the authors found that high levels of serum estrogen were associated with the upregulation of prolactin and synaptotagmin IV, while treatment with L-dopa downregulated Syt IV.

More information:
Zorovic M, Kolmančič K, Živin M. Effects of L-dopa on expression of prolactin and synaptotagmin IV in 17-beta-estradiol-induced prolactinomas of ovariectomized hemiparkinsonian rats. Bosn J of Basic Med Sci. 2021Mar.28. Available from: www.bjbms.org/ojs/index.php/bj … ms/article/view/5491; DOI: doi.org/10.17305/bjbms.2021.5491

Provided by Association of Basic Medical Sciences of FBIH

Citation: Hormone replacement therapy in patients with Parkinson’s disease (2021, June 8) retrieved 14 September 2025 from https://sciencex.com/wire-news/384605894/hormone-replacement-therapy-in-patients-with-parkinsons-disease.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
Back to list